These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
753 related articles for article (PubMed ID: 30547810)
21. Epigenetic Modulation of SPCA2 Reverses Epithelial to Mesenchymal Transition in Breast Cancer Cells. Makena MR; Ko M; Dang DK; Rao R Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445642 [TBL] [Abstract][Full Text] [Related]
22. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095 [TBL] [Abstract][Full Text] [Related]
23. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463 [TBL] [Abstract][Full Text] [Related]
25. Targeting triple negative breast cancer with histone deacetylase inhibitors. Fedele P; Orlando L; Cinieri S Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409 [TBL] [Abstract][Full Text] [Related]
26. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis. Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782 [TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
28. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232 [TBL] [Abstract][Full Text] [Related]
29. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283 [TBL] [Abstract][Full Text] [Related]
30. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103 [TBL] [Abstract][Full Text] [Related]
31. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. Kim S; Lee J; Jeon M; Nam SJ; Lee JE Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755 [TBL] [Abstract][Full Text] [Related]
32. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952 [TBL] [Abstract][Full Text] [Related]
33. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling. Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K Cells; 2019 Aug; 8(8):. PubMed ID: 31416135 [TBL] [Abstract][Full Text] [Related]
34. SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2. Steed KL; Jordan HR; Tollefsbol TO Anticancer Res; 2020 Jan; 40(1):9-26. PubMed ID: 31892549 [TBL] [Abstract][Full Text] [Related]
35. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424 [TBL] [Abstract][Full Text] [Related]
36. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Schech A; Kazi A; Yu S; Shah P; Sabnis G Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781 [TBL] [Abstract][Full Text] [Related]
37. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818 [TBL] [Abstract][Full Text] [Related]
38. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway. Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686 [TBL] [Abstract][Full Text] [Related]
39. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling. Li B; Huang L; Ruan J Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372 [TBL] [Abstract][Full Text] [Related]
40. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]